| 1 |
Clinical Phase 2a Development of BX-001N for the Treatment of Acute Kidney Injury by Inhibiting Ischemia-Reperfusion Injury |
| Others-Synth. |
CSA-AKI |
Reactive Oxygen Species (ROS; H2O2, O2-, •OH, others), Keap1 |
Phase 2 |
Bilix |
RS-2026-25501760 |
|
| 2 |
A Phase 2b Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Evaluate the Efficacy and Safety of Isuzinaxib in Subjects with Diabetic Kidney Disease (PROMISS-DKD) |
| Small molecules |
Diabetic nephropathy |
pan-NOX 저해제 (NOX1,2,3,4,5, DUOX1,2) |
Phase 2 |
Aptabio |
RS-2025-02073057 |
|
| 3 |
Development of new drug Vonifimod for the treatment of Alopecia Areata |
| Small molecules |
Alopecia areata |
S1PR1&4 |
Phase 2 |
NEXTGEN Bioscience |
RS-2024-00332313 |
|
| 4 |
A Phase 2b clinical study for iron.based T1.MRI contrast agent: Advancing towards Phase 3 |
| Others-Synth. |
Lymphadenopathy |
Arthrography using magnetic resonance imaging (MRI) for shouler, hip, elbow, knee, wrist, and ankle |
Phase 2 |
Inventera Pharmaceuticals Inc. |
RS-2023-00282888 |
|
| 5 |
Clinical Trial Development of Small Molecule Inhibitor for Progeria Treatment: Progerinin |
| Small molecules |
Progeria syndromes |
Progerin PPI |
Phase 2 |
PRG S&Tech Inc. |
RS-2023-00258708 |
|
| 6 |
Development of a HNP-2006 contrast agent with improved safety |
| Others-Synth. |
MRI contrast agent |
Gd-ligand |
Phase 2 |
Hana Pharm Co., Ltd. |
HN21C1298 |
|